|
"As people live longer, improving quality of life is paramount," said Alex Morgan, a partner at Khosla Ventures, who chipped in to fund Rubedo's first round of venture capital financing. "Rubedo is targeting senescent, or aging, cells that drive age-related disease. This first trial can bring us another step closer to achieving better healthspan."
Continue Reading
Medical, Science
anti-aging,
|
|